The Technical Analyst
Revance Therapeutics Inc [RVNC]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Revance Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-3.70% $3.64
America/New_York / 22 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 379.35 mill |
| EPS: | -3.83 |
| P/E: | -0.950 |
| Earnings Date: | May 06, 2024 |
| SharesOutstanding: | 104.22 mill |
| Avg Daily Volume: | 1.795 mill |
| RATING 2024-04-22 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Sell | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.950 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.16x |
| Company: PE -0.950 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 3.24 - 4.04 ( +/- 11.07%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-16 | Jordan Erica | Sell | 2 392 | Common Stock |
| 2024-03-15 | Sjuts Dustin S | Sell | 2 967 | Common Stock |
| 2024-03-18 | Sjuts Dustin S | Sell | 9 211 | Common Stock |
| 2024-03-15 | Moxie Dwight | Sell | 3 269 | Common Stock |
| 2024-03-18 | Moxie Dwight | Sell | 8 125 | Common Stock |
| INSIDER POWER |
|---|
| 64.35 |
| Last 97 transactions |
| Buy: 2 720 068 | Sell: 629 333 |
Forecast:
16:00 - $3.64
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $3.64
Forecast 2: 16:00 - $3.64
Forecast 3: 16:00 - $3.64
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $3.64 (-3.70% ) |
| Volume | 1.602 mill |
| Avg. Vol. | 1.795 mill |
| % of Avg. Vol | 89.30 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For RVNC
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $5.37 | N/A | Active |
|---|
RVNC
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DaxibotulinumtoxinA in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Last 10 Buy Signals
Latest Press Releases
2024-04-12 08:00:00 - Press Release
Revance To Present New Daxxify® Data At The American Academy Of Neurology 2024 Annual Meeting
Nashville, tenn.--(business wire)--revance to present new daxxify® data at the american academy of neurology 2024 annual meeting.
2024-03-27 16:05:00 - Press Release
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nashville, tenn.--(business wire)--revance reports inducement grants under nasdaq listing rule 5635(c)(4).
2024-03-04 09:25:00 - Press Release
Revance Announces Pricing Of $100.0 Million Public Offering Of Common Stock
Nashville, tenn.--(business wire)--revance announces pricing of $100 million public offering of common stock.
2024-03-04 06:37:00 - Press Release
Revance Announces Proposed Public Offering Of Common Stock
Nashville, tenn.--(business wire)--revance announces proposed public offering of common stock.
2024-02-28 16:05:00 - Press Release
Revance Reports Fourth Quarter And Full Year 2023 Financial Results, Provides Corporate Update
Nashville, tenn.--(business wire)--revance reports fourth quarter and full year 2023 financial results, provides corporate update.
Latest News
2024-04-12 08:00:00 - Business Wire
Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting.
2024-02-21 08:01:00 - Business Wire
Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024.
2023-11-08 22:50:20 - Seeking Alpha
Revance Therapeutics, Inc. (RVNC) Q3 2023 Earnings Call Transcript
Revance Therapeutics, Inc. (NASDAQ:RVNC ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Jessica Serra - Head, IR, Communications & ESG Mark Foley - CEO Dustin Sjuts - President Toby Schilke - CFO Conference Call Participants Seamus Fernandez - Guggenheim Partners Mikaela Franceschina - Barclays David Amsellem - Piper Sandler Stacy KU - TD Cowen Annabel Samimy - Stifel Uy Ear - Mizuho Serge Belanger - Needham and Company Douglas Tsao - H.C. Wainwright Terence Flynn - Morgan Stanley Navann Ty - BNP Paribas Operator Welcome to the Revance Therapeutics Third Quarter 2023 Financial Results and Corporate Update Conference Call.
2023-11-08 20:17:12 - Zacks Investment Research
Revance Therapeutics, Inc. (RVNC) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Revance Therapeutics, Inc. (RVNC) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
2023-09-15 17:51:50 - Seeking Alpha
Revance Therapeutics: Impressive Sales Growth/Concerning Cash Burn
Revance Therapeutics, Inc. stock has fallen by half in the past six months, despite impressive sales growth, prompting speculation on whether it is now a good buy. The recent DAXXIFY launch seems to be proceeding well, but quarterly cash burn remains an issue as Revance challenges Botox in this space. Analysts have mixed opinions on the stock, with some reiterating buy ratings and others issuing neutral ratings.
2023-09-06 14:27:04 - InvestorPlace
3 Healthcare Stocks to Sell in September Before They Crash & Burn
The healthcare industry comprises multiple sectors, including biotechnology, pharmaceuticals, and healthcare equipment, each offering a unique and potentially risky opportunity. News regarding FDA approval and positive results for therapies, pharmaceuticals, and trials greatly influences the outlook for companies, especially ones with small market cap share price.
2023-08-29 00:43:00 - InvestorPlace
3 Very Oversold Biotech Stocks to Buy Right Now
After I spent many years following Wall Street, there are a few characteristics about the “big money” that stand out for me. One of these traits is that many if not most large investors are very reluctant to buy stocks that have a 60%-80% chance of climbing a great deal in the long term but a 10%-15% chance of plunging in the short-to-medium term.
2023-08-14 08:53:00 - Market Watch
Revance shares gain 8% after FDA approval of cervical dystonia treatment
Shares of Revance Therapeutics Inc. RVNC, -3.81% gained 8% premarket on Monday after the U.S. Food and Drug Administration approved the biotech company's Daxxify injection for treatment of cervical dystonia in adults. Cervical dystonia is a chronic disease that causes painful, involuntary neck muscle contractions and affects about 60,000 people in the U.S. Daxxify, a Botox competitor, previously received FDA approval late last year for the temporary improvement of frown lines.
2023-08-14 08:06:04 - Reuters
Revance's Botox rival gets FDA approval for painful neck muscle condition
The U.S. health regulator has approved expanding the use of Revance Therapeutics' Daxxify to treat a painful neck muscle condition, intensifying the anti-wrinkle injection's rivalry with AbbVie's Botox.
2023-08-08 19:41:55 - Zacks Investment Research
Revance Therapeutics, Inc. (RVNC) Reports Q2 Loss, Tops Revenue Estimates
Revance Therapeutics, Inc. (RVNC) came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $0.88 per share a year ago.